Bioliberty raises €2.95 million for home rehabilitation

Bioliberty raised €2.95 million ($3.3 million) in a Series A extension, lifting its total funding to €12.07 million ($13.5 million). The Edinburgh- and Boston-based rehabilitation technology startup will use the capital to bring its soft-robotic therapy and AI-supported clinical tools into the home. It also plans to connect rehabilitation data across hospital, post-acute and home settings.

The extension added four new institutional backers: TGH Ventures, the investment arm of Tampa General Hospital; Ballad Ventures; Belfast-based Whiterock; and 25m Health. Bioliberty said the extension builds on €9.12 million ($10.2 million) previously raised through its pre-Series A and Series A rounds.

Rowan Armstrong, co-founder and CEO of Bioliberty, said: “This funding and our new strategic investors are crucial to our next phase: creating a more connected rehabilitation journey. We want to connect data across the patient journey, extend our technology into the home, and use AI to further augment therapy and assessment for physical and occupational therapists.”

What will the new capital fund?

Bioliberty said the extension supports three major priorities in the company’s next phase:

• Extend its rehabilitation technology into the home environment.
• Connect rehabilitation data across different care settings.
• Build additional AI capabilities that support clinical decision-making.

The stated priorities put home deployment, shared clinical data and AI development on one funding track. Bioliberty says it wants its technology to help ensure recovery does not stop when a patient leaves a rehabilitation facility.

How does Bioliberty’s system work?

Bioliberty develops soft-robotic rehabilitation technology focused on upper-extremity recovery, primarily for patients who have suffered strokes or other mobility-limiting neurological conditions. Its wearable glove uses air power to assist patients in opening and strengthening their hands.

Armstrong, Ross O’Hanlon, Conan Bradley and Shéa Quinn founded Bioliberty in 2020. All four founders hail from Northern Ireland. Armstrong serves as co-founder and CEO, while the company is based in Edinburgh and Boston.

The product suite has three connected components:

• Lifehub, a portable control centre that powers the system and delivers interactive therapy sessions.
• Lifeglov, a soft robotic wearable glove powered by air that assists patients in opening and strengthening their hands.
• Lifemind, a clinician-facing dashboard that centralises therapy data and uses AI to auto-generate clinical notes.

Bioliberty reported that Lifehub and Lifeglov are FDA-listed in the United States. The company launched commercially in that market in 2025. Its work with U.S. rehabilitation providers included a 2024 clinical study with the Mount Sinai health system.

Bioliberty says it co-developed its technology with leading inpatient rehabilitation facilities. The company says therapists can begin a session in under five minutes and that patients can complete more repetitions during each session.

Ethan Clark, Therapy Manager at Methodist Rehabilitation Hospital, said: “Bioliberty has been implemented by our therapists seamlessly. Patients are excited to see gains in their function and enjoy the interactivity of the tasks and games they can access.”

Under the plan, Bioliberty will use the extension to extend the technology into homes and connect data from different care settings. The initiative builds on the company’s U.S. commercial launch in 2025 and its 2024 clinical study with the Mount Sinai health system. It also supports additional AI features for clinical decision-making, alongside AI-generated notes in Lifemind.

Why does Bioliberty want rehabilitation at home?

Bioliberty wants to become an end-to-end rehabilitation platform spanning hospital, post-acute and home settings. The company wants its technology to help ensure recovery does not stop when a patient leaves a rehabilitation facility. Bioliberty said it has a U.S. base in Boston and partnerships with some of the most prominent rehabilitation providers in the country.

Bioliberty’s next phase hinges on linking home use to hospital and post-acute data while adding AI tools for therapists and clinical decisions. The Series A extension gives the company capital to pursue that connected-care model as it expands beyond its existing U.S. hospital relationships.